September 14, 2021
1 min learn
Takamori S, et al. Summary MA15.07. Offered at: Worldwide Affiliation for the Examine of Lung Most cancers World Convention on Lung Most cancers (digital assembly); Sept. 8-14, 2021.
Takamori studies an advisory board function with Guardant Well being, in addition to journey charges or honoraria from Boehringer Ingelheim and Merck. Please see the summary for all different researchers’ related monetary disclosures.
Older sufferers with late-stage non-small cell lung most cancers appeared to benefit from immunotherapy, in keeping with outcomes introduced at Worldwide Affiliation for the Examine of Lung Most cancers World Convention on Lung Most cancers.
“Immune perform is impaired [among] older patients, however whether or not these patients benefit from immune checkpoint inhibitors was unclear,” Shinkichi Takamori, MD, researcher within the division of thoracic oncology at Nationwide Hospital Group of the Kyushu Most cancers Heart in Japan, advised Healio. “As well as, older sufferers are sometimes excluded from scientific trials; due to this fact, scientific benefit from immunotherapy in day by day observe is unknown.”
Researchers used the Nationwide Most cancers Database to determine 86,173 sufferers with stage IV NSCLC handled between 2014 and 2015.
The evaluation included 24,136 sufferers aged 75 years or older (immunotherapy, n = 2,241; no immunotherapy n = 21,895) and 62,037 sufferers aged youthful than 75 years (immunotherapy, n = 8,968; no immunotherapy, n = 53,069).
Researchers in contrast OS between sufferers who acquired immunotherapy and people who didn’t.
Univariate evaluation confirmed a survival benefit with immunotherapy amongst sufferers aged 75 years or older (median OS, 11.9 months vs. 5.4 months; HR = 0.61; 95% CI, 0.58-0.64), in addition to amongst these aged youthful than 75 years (median OS, 14.5 months vs. 7.8 months; HR = 0.67; 95% CI, 0.65-0.68).
Multivariate evaluation confirmed a survival benefit with immunotherapy in each age teams, exhibiting poorer survival for sufferers who didn’t obtain immune checkpoint inhibitors amongst these aged 75 years or older (HR = 1.63; 95% CI, 1.55-1.71) and amongst these aged youthful than 75 years (HR = 1.5; 95% CI, 1.46-1.54).
“If aged sufferers can not obtain cytotoxic chemotherapy because of decrease practical capability or poor efficiency standing, oncologists can introduce them to immune checkpoint inhibitors as a remedy possibility,” Takamori stated. “This examine means that immune checkpoint inhibitor monotherapy is useful for aged sufferers and that the mixture of immune checkpoint inhibitor plus chemotherapy can also be a normal first-line remedy.
“Some subgroup analyses of aged sufferers from the scientific trial indicated that mixture remedy of immunotherapy and chemotherapy is extra helpful to youthful sufferers in contrast with aged sufferers,” Takamori added. “Additional examine is required to analyze whether or not immune checkpoint inhibitor monotherapy or mixture remedy is acceptable for older [patients with lung cancer].”